POST-TRANSLATIONAL MODIFICATIONS OF ANTIBODIES: WHERE THERE’S SMOKE THERE’S FIRE

Rene Toes. Leiden University Medical Center, Rheumatology, Leiden, Netherlands

Rheumatoid arthritis (RA) is a prototype autoimmune disease, with the hallmark signs of synovial inflammation and the presence of autoantibodies. One of the most prominent examples of such autoantibodies are anti-citrullinated protein antibodies (ACPA), which are directed against a wide-array of citrullinated proteins in the immune system (1). Despite antigens is a dynamic response that expands before the onset of disease and generates antibodies that are extensively glycosylated in the variable domain. This feature of ACPAs is remarkable and might be involved in the breach of tolerance to citrullinated proteins as well as function as an additional biomarker to predict disease onset in subjects at risk.

Next to ACPA, it has become clear that the autoantibody response in RA extends far beyond citrullinated proteins. The immune response to citrullinated antigens is a dynamic response that expands before the onset of disease and generates antibodies that are extensively glycosylated in the variable domain. This feature of ACPAs is remarkable and might be involved in the breach of tolerance to citrullinated proteins as well as function as an additional biomarker to predict disease onset in subjects at risk.

Pathogenic Antibodies in Phospholipid Syndrome

Sasa Cucurela. University Medical Center Ljubljana, Department of Rheumatology, Immunology Laboratory, Ljubljana, Slovenia

Antiphospholipid syndrome (APS) is a prothrombotic systemic autoimmune disorder characterized with multisystem manifestation, most commonly venous and arterial thromboembolism and/or recurrent pregnancy loss. The varying clinical phenotype is associated with heterogeneity in the pathogenic antiphospholipid antibodies (aPL) that are central to the diagnosis of APS. According to the international consensus statement on classification criteria, APS is classified when persistently elevated levels of specific aPL, such as lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-beta2-glycoprotein I (anti-β2GPI) antibodies, are confirmed in addition to clinical manifestations (1, 2). The exact pathogenesis of APS is unknown, but aPL have been described to activate monocytes, neutrophils, dendritic cells and placental tissue (3). Despite the fact that many different proteins have been identified as being involved in the pathogenesis of APS, accumulating evidence from in vitro experiments as well as animal studies has revealed that β2GPI is the main target for aPL. It was also shown that triple aPL positivity, defined by detection LA, high titers of aCL and anti-β2GPI antibodies, correlates better with both thrombosis and pregnancy morbidity than any other aPL profile (4).

Several autoantibodies outside those included in APS classification criteria could be also relevant to APS pathogenesis (5) and therefore, antibodies against other antigen targets have been investigated. Current evidence shows that some of these antibodies, particularly antibodies against domain I of β2GPI (anti-DI-β2GPI) and phosphatidylserine dependent anti-prothrombin antibodies (aPS/PT) might be relevant in the better recognition of APS patients. These antibodies are commonly referred as non-criteria aPL (6) because they have not been yet accepted as laboratory criterion for the diagnosis of APS. The DI of β2GPI has been identified as the most relevant antigen target involved in β2GPI/anti-β2GPI antibody binding. Anti-DI-β2GPI antibodies were found to be strongly related to thrombosis and pregnancy complication and are more frequently detected in patients with APS than in asymptomatic aPL carriers (7). High titers of anti-DI-β2GPI are also frequently present in triple aPL positive patients. Nevertheless, it is far too soon to recommend replacement of anti-β2GPI testing with an anti-DI-β2GPI antibody assay because it was shown that about 30% of patients with anti-β2GPI antibodies are negative for anti-DI-β2GPI antibodies (8). The clinical significance of autoantibodies reacting with epitopes other than DI was also investigated in multicenter study (9). The results showed a diverse clinical association with reactivity to different epitopes on β2GPI, suggesting all domains were relevant. Therefore, more detailed profiling of domain specificity and avidity of anti-β2GPI antibodies may be useful as risk stratification for clinical events.

APS/PT antibodies also represent strong risk factor for thrombosis. Results of multicenter study demonstrated that IgG aPS/PT detection might contribute to a better and more reliable identification of APS patients (10). Due to the heterogeneity of aPL (criteria and non-criteria) the interpretation of aPL results is huge challenge in daily routine practice and should always be related to clinical symptoms and therefore, interaction between the laboratory and clinician is essential.

REFERENCES:


Disclosure of Interests: None declared


SP0176

Impact of Checkpoint Inhibitors on B Cells

David Pisetsky. Duke University Medical Center, Medicine/Immunology, Durham, North Carolina, United States of America

Immune checkpoint inhibitors (ICI) are a new class of biological agents that has revolutionized the treatment of cancer. Unlike conventional cytotoxic agents that

Disclosure of Interests: None declared
